Direkt zum Inhalt
Merck

Wichtige Dokumente

Gesamtdokumentation anzeigen

Fortfahren mit

SML2263

Ladostigil tartrate

≥98% (HPLC)

Synonym(e):

(3R)-(N-Propargylaminoindan-5-yl)-ethyl methyl carbamate tartrate (2:1), TV-3326, TV3326

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern
PackungsgrößeSKUVerfügbarkeitPreis
5 mg
Warenkorb auf Verfügbarkeit prüfen
€ 72,70
€ 61,79
25 mg
Warenkorb auf Verfügbarkeit prüfen
€ 292,00
€ 248,20

Über diesen Artikel

Empirische Formel (Hill-System):
C16H20N2O2 · 0.5C4H6O6
CAS-Nummer:
209394-46-7
Molekulargewicht:
347.39
UNSPSC Code:
12352200
MDL number:
MFCD22741393
NACRES:
NA.21
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated

€ 61,79

Listenpreis€ 72,70Sparen Sie 15%
Aktion nur im Web
Warenkorb auf Verfügbarkeit prüfen
​
Großbestellung anfragen
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

H2O: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

N([C@@H]3CCc4c3cc(cc4)OC(=O)N(CC)C)CC#C.N([C@@H]1CCc2c1cc(cc2)OC(=O)N(CC)C)CC#C.O[C@H]([C@@H](O)C(=O)O)C(=O)O

InChI

1S/2C16H20N2O2.C4H6O6/c2*1-4-10-17-15-9-7-12-6-8-13(11-14(12)15)20-16(19)18(3)5-2;5-1(3(7)8)2(6)4(9)10/h2*1,6,8,11,15,17H,5,7,9-10H2,2-3H3;1-2,5-6H,(H,7,8)(H,9,10)/t2*15-;1-,2-/m111/s1

InChI key

PRLVBVAJMQZMJN-OGOSNNLPSA-N

Biochem/physiol Actions

Ladostigil, a carbamate is also a butyryl cholinesterase (BuChE) inhibitor.[1] It possesses anti-inflammatory property and effectively reduces the levels of tumor necrosis factor α (TNF-α) in lipopolysaccharide (LPS)-activated macrophages.[1] It provides protection to cardiomyocytes.[2] Ladostigil has neuroprotective functionality and has the potential to treat mild cognitive impairment (MCI) and spatial memory deficits development.[3] It also exhibits protective effects during oxidative and nitrative stress.[3]
Multifunctional drug designed to treat Alzhemier′s disease by combining in a single molecule the neuroprotective/neurorestorative effects of the (MAO)-B inhibitor rasagiline with the cholinesterase (ChE) inhibitory activity of rivastigmine.
Multifunctional drug designed to treat Alzhemier′s disease by combining in a single molecule the neuroprotective/neurorestorative effects of the (MAO)-B inhibitor rasagiline with the cholinesterase (ChE) inhibitory activity of rivastigmine.

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 1

Dieser Artikel
SML2351SML0881M5449
Ladostigil tartrate ≥98% (HPLC)

Sigma-Aldrich

SML2263

Ladostigil tartrate

Dabigatran etexilate ≥98% (HPLC)

Sigma-Aldrich

SML2351

Dabigatran etexilate

Rivastigmine tartrate ≥98% (HPLC)

Sigma-Aldrich

SML0881

Rivastigmine tartrate

MKT-077 ≥98% (HPLC), powder

Sigma-Aldrich

M5449

MKT-077

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

form

powder

form

powder

form

powder

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage condition

desiccated

storage condition

-

storage condition

desiccated

storage condition

-

solubility

H2O: 2 mg/mL, clear

solubility

DMSO: 2 mg/mL, clear

solubility

H2O: 15 mg/mL, clear

solubility

H2O: 10 mg/mL, clear

color

white to beige

color

white to beige

color

white to beige

color

orange to red

Lagerklasse

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
0000185160
0000185162
0000167599
0000185162
0000185160

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Rony Panarsky et al.
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 7(2), 488-498 (2012-03-29)
Impaired mitochondrial function accompanied by microglial activation and the release of nitric oxide (NO) and pro-inflammatory cytokines has been reported in Alzheimer's disease, its prodromal phase of Mild Cognitive Impairment (MCI) and in aged rats. The present study showed that
John P M Finberg et al.
Frontiers in pharmacology, 7, 340-340 (2016-11-03)
Inhibitors of MAO-A and MAO-B are in clinical use for the treatment of psychiatric and neurological disorders respectively. Elucidation of the molecular structure of the active sites of the enzymes has enabled a precise determination of the way in which
Orly Weinreb et al.
British journal of pharmacology, 173(13), 2080-2094 (2015-09-04)
Alzheimer's disease (AD) is accepted nowadays as a complex neurodegenerative disorder with multifaceted cerebral pathologies, including extracellular deposition of amyloid β peptide-containing plaques, intracellular neurofibrillary tangles, progressive loss of cholinergic neurons, metal dyshomeostasis, mitochondrial dysfunction, neuroinflammation, glutamate excitoxicity, oxidative stress
Alle zugehörigen Dokumente anzeigen

Global Trade Item Number

SKUGTIN
SML2263-25MG04061835504954
SML2263-5MG04061835504961

Questions

Reviews

No rating value

Active Filters